Skip to main content

FDA Clears Sickle Cell Drug, Casgevy, to Treat Transfusion-Dependent Beta-Thalassemia

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 17, 2024.

By Robin Foster HealthDay Reporter

WEDNESDAY, Jan. 17, 2024 -- Casgevy, a groundbreaking treatment that was approved to treat sickle cell disease in December, was given the U.S. Food and Drug Administration's blessing on Tuesday to treat another inherited blood disorder.

Casgevy is the first CRISPR-based medicine, where gene editing is used to develop the treatment, to be approved for use in the United States.

The one-time dose permanently changes DNA in a patient’s blood cells, but experts note the relief will not come cheap. The treatment list price is $2.2 million for its use in both sickle cell disease and beta thalassemia, CNN reported.

This latest approval allows Casgevy to be used in patients over the age of 12 with transfusion-dependent beta-thalassemia. With this disorder, the body doesn't make enough of the oxygen-carrying molecule in blood known as hemoglobin.

“Today’s approval is an important step in the advancement of an additional treatment option for individuals with beta-thalassemia, a debilitating disease that places individuals at risk of many serious health problems,” Dr. Nicole Verdun, director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research, said in an agency news release.

“The approval of a cell-based gene therapy for this condition using CRISPR/Cas9 technology reflects FDA’s continued commitment to supporting safe and effective treatments that leverage the most promising and cutting-edge medical technologies,” she added.

In December, the FDA approved Casgevy to treat sickle cell disease, an inherited blood disorder that typically strikes Black people.

"Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited," Verdun noted at the time of that approval.

The FDA’s latest decision was expected, but it comes about two months earlier than the agency’s deadline for acting, CNN reported.

To make Casgevy, a person’s stem cells are removed and modified using a gene-editing technique called CRISPR/Cas9. The altered cells are then transplanted back into the patient's body, where they multiply and increase the production of hemoglobin, which eases symptoms.

The most common side effects with Casgevy were mouth sores, fever associated with a low level of certain white blood cells and decreased appetite, according to the FDA.

With beta thalassemia, a person can become anemic, which makes them feel weak, tired and out of breath. It can shorten a person’s life, and the only treatment in the past has been frequent blood transfusions.

Unfortunately, repeated transfusions can trigger another problem called iron overload syndrome, which then has to be managed with other treatments. There are at least 1,200 people in the United States with thalassemia severe enough that it must be managed with blood transfusions, according to Boston Children’s Hospital.

Sources

  • U.S. Food and Drug Administration, news release, Jan. 16, 2024
  • CNN

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

Read this next

COVID Can Threaten Sickle Cell Patients, But Too Few Are Vaccinated

FRIDAY, Jan. 12, 2024 -- Sickle cell disease is one of many chronic health conditions that dramatically increases the risk of hospitalization and death in people infected by...

FDA Approves Landmark Sickle Cell Gene Therapies, Casgevy and Lyfgenia

FRIDAY, Dec. 8, 2023 -- The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved...

FDA Advisors Say New Gene Therapy for Sickle Cell Disease, Exa-cel, is Safe

WEDNESDAY, Nov. 1, 2023 -- A new gene therapy for sickle cell disease was deemed safe by a U.S. Food and Drug Administration advisory panel on Tuesday, paving the way for...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.